Abiraterone (Zytiga), a novel agent for the management of castration-resistant prostate cancer

摘要

Prostate cancer is the second most common cancer diagnosed in men living in the U.S. The disease was expected to account for more than 28,000 deaths in 2012, and more than 241,700 new cases were expected to be diagnosed that year. Prostate cancer usually affects men after the age of 40. Besides age, other risk factors include ethnicity, dietary practices, and genetic predisposition. The highest incidence is seen in African-American patients, followed by Caucasian and Hispanic patients, respectively (Ta-ble 1) .